Sussex Innovation Centre drug discovery company awarded £29m to tackle lung diseases
Posted on behalf of: University of Sussex
Last updated: Tuesday, 21 January 2020
A drug discovery company based at the Sussex Innovation Centre, a wholly owned subsidiary of the University of Sussex, has attracted £29 million in funding to help fight respiratory diseases.
Enterprise Therapeutics Ltd attracted investment from an international consortium of top tier venture capital investors to help develop new therapies for conditions such as cystic fibrosis and severe asthma. Enterprise Therapeutics benefits from a close working relationship with the School of Life Sciences at the University of Sussex.
Chief Scientific Officer for Enterprise Therapeutics and Professor of Molecular Pharmacology at Sussex, Martin Gosling, said: “This is a truly exciting moment in drug discovery as we seek to tackle some of the most debilitating respiratory diseases out there.
“Attracting this syndicate of leading life science investors is a reflection of what the company has achieved to date and the strength of our research and development. We’re looking forward to a bright future in the field of respiratory medicine.”
The leadership team of Enterprise Therapeutics Ltd was singled out for praise by investors. Senior managers have significant expertise in drug discovery, drug development, respiratory biology and ion channel pharmacology.
The investment syndicate included Versant Ventures, Novartis Venture Fund, Forbion, Epidarex Capital and IP Group.